A groundbreaking immunotherapy candidate, now in clinical trials, offers a powerful dual response against cancer. This small molecule increases the activity of immune cells while making tumors more susceptible to immune attack. Developed by researchers...

Researchers from the Broad, Abbvie, and Calico Life Sciences have developed a new cancer immunotherapy candidate — now being tested in an early-stage clinical trial — that may provoke a potent response in both cancer and immune cells. Project leaders...

High-affinity MHC I-peptide interactions are considered essential for immunogenicity. However, some neo-epitopes with low affinity for MHC I have been reported to elicit CD8 T cell dependent tumor rejection in immunization-challenge studies. Here we show...

Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance1,2. The protein tyrosine phosphatases PTPN2 and PTPN1 are central regulators...